ArticleJournal of medical biochemistry2025
Effects of ginkgo diterpene lactone glucosamine combined with clopidogrel on hemodynamics, neurocytokines, and inflammatory responses in patients with cerebral infarction complicated by coronary heart disease.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ginkgo biloba L. in preventing cardiovascular disease: pharmacological effects, mechanism of action, and therapeutic potential.Acta pharmacologica Sinica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the effects of Ginkgo Diterpene Lactone Meglumine (GM) combined with Clopidogrel (CLO) on hemodynamics, neurocytokines, and inflammatory responses in patients with cerebral infarction (CI) complicated by coronary heart disease (CHD). Methods: A total of 152 patients diagnosed with CI complicated by CHD, admitted to our hospital between January 2024 and October 2024, were enrolled in the study. Among them, 81 patients received CLO monotherapy (control group), while the remaining 71 patients were treated with a combination of CLO and GM (observation group). Hemodynamic parameters, including plasma viscosity (PV), whole blood high (WBHSV) and low shear viscosity (WBLSV), as well as reduced viscosity (RV), were measured before and after treatment. Platelet adhesion test (PAdT) and platelet aggregation test (PAgT) were also performed. Inflammatory markers and neurocytokines were assessed using enzyme-linked immunosorbent assays, and adverse reactions during treatment were documented. Results: After treatment, both groups exhibited significant reductions in PAdT, PAgT, PV, WBHSV, WBLSV, and RV compared to baseline (P<0.05). However, PAdT, PAgT, WBHSV, WBLSV and RV were lower in the observation group compared to the control group (P<0.05). Additionally, the observation group showed lower levels of neuron-specific enolase, glial fibrillary acidic protein, tumor necrosis factor-a, and hypersensitive C-reactive protein, along with higher levels of brain-derived neurotrophic factor, compared to the control group (P<0.05). No significant difference was observed in the incidence of adverse reactions between the two groups (P>0.05). Conclusions: The combination of GM and CLO is more effective than CLO monotherapy in improving hemodynamics, enhancing neurological function, and mitigating inflammatory responses in patients with CI complicated by CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.